Aspen Neuroscience, Inc., a clinical-stage biotechnology company pioneering autologous regenerative therapies,  announced the closing of a $115 million Series C financing round. This significant investment will fuel the continued clinical development of Aspen's lead program, ANPD001, for moderate to advanced Parkinson's disease.

The Series C round was co-led by OrbiMed, ARCH Venture Partners, Frazier Life Sciences, and Revelation Partners, with participation from existing investors including Medical Excellence Capital, S32, Axon Ventures, LYFE Capital, and LifeForce Capital, among others. New investors include Kite, a Gilead Company  (Nasdaq:GILD), Balyasny Asset Management, Cormorant Asset Management, Prebys Ventures, and others. This latest funding brings Aspen's total capital raised to date to over $340 million, including an $8 million grant from California Institute for Regenerative Medicine (CIRM).

In conjunction with the financing, Cindy Perettie, Executive Vice President and Global Head of Kite, a Gilead Company, will join Aspen's board of directors.

"This financing marks a pivotal moment for Aspen as we accelerate our mission to deliver personalized regenerative therapies for people with Parkinson's disease and beyond," said Damien McDevitt, Ph.D, President and Chief Executive Officer of Aspen Neuroscience. "We are grateful for the confidence our investors have shown in our science, team, vision, and market opportunity. The significant experience and deep capital resources our investor syndicate brings will be instrumental in advancing Aspen's next phases of clinical development and commercial readiness. Their strategic guidance and financial support empower us to scale our operations, expand our pipeline, and bring transformative therapies closer to those in need."

Advancing Clinical Innovation and Commercial Readiness

The Series C financing will be used to:

• Support ongoing clinical trials of ANPD001, Aspen's lead autologous cell therapy candidate for Parkinson's disease.
• Scale manufacturing capabilities to meet clinical and future commercial demand.
• Advance Aspen's pipeline of autologous iPSC-derived therapies for additional neurological indications.

Aspen's proprietary manufacturing platform leverages machine learning and advanced genomics to produce the highest quality personalized cells for each patient, setting a new benchmark for consistency and scalability in cell therapy.

This financing follows initiation of dosing for the Phase 1/2a Cohort 3 commercial formulation and presentation of promising safety and efficacy data at six months post-procedure for Cohort 1.

"It is significant to see a private financing of this quality. Securing this round is a testament to how this team is rising above with innovation in product characterization, manufacturing automation, and positive clinical results," said Faheem Hasnain, Board Chairman of Aspen Neuroscience. "Aspen is poised to deliver the first potentially disease-modifying therapy for the millions of patients waiting for these advancements."